Pfs25 is a sexual stage antigen of Plasmodiumfakiparum that is expressed on the surface of zygote and ookinete forms of the parasite. Monoclonal antibodies directed against native Pfs25 can block completely the development ofP. fakiparum oocysts in the midgut of the mosquito vector. Thus, this 25-kD protein is a potential vaccine candidate for eliciting transmission-blocking immunity in inhabitants of malaria endemic regions. We have synthesized, by secretion from yeast, a polypeptide analogue of Pfs25 that reacts with conformation-dependent monoclonal antibodies, and elicits transmission-blocking antibodies when used to immunize mice and monkeys in conjunction with a muramyl tripeptide adjuvant. Our results suggest the further evaluation of recombinant DNAo derived Pfs25 in transmission-blocking vaccination studies in humans.
T
he increasing resistance to chemotherapy of the parasites responsible for human malaria has reaffirmed the requirement for an effective malaria vaccine. Subunit vaccine strategies using either peptide synthesis or recombinant DNA technologies have been focused primarily on the immunization of the human host against asexual forms of the parasite. For example, well-studied vaccination approaches have targeted the induction of neutralizing responses against the sporozoite form of the parasite that is injected by the mosquito vector during a blood meal. Also, merozoite and erythrocytic-stage antigens have been considered as immunogens for the suppression of parasitemia in susceptible individuals. An alternative approach for the control of endemic malaria in devdoping countries is that of transmission-blocking vaccination. Here, it has been proposed that such a strategy could prevent the transmission of viable sexual forms of the parasite from humans to mosquitoes. Foremost among transmission-blocking vaccine candidates is the Plasmodium fakiparum surface protein Pfs25. This 25-kD polypeptide is expressed on the surface of zygote and ookinete forms of the parasite as they develop in the midgut of the mosquito vector (1) . mAbs to Pfs25 have been shown to block fully the development of sexual stages of the parasite (1, 2) , and vaccinia virus recombinants that express Pfs25 can induce transmission-blocking antibodies in MHC-disparate congenic mice (3) . Such studies have suggested that the production of large quantities of synthetic Pfs25 peptides, or recombinant Pfs25 protein, together with recreation of the appropriate conformation orB cell epitopes for immunological activity in vivo are required for the development of Pfs25 as a human vaccine. Here, we show that an analogue of Pfs25, synthesized by secretion from yeast, reacts with conformation-dependent mAbs, and can elicit transmission-blocking antibodies when used to immunize mice and monkeys in conjunction with a muramyl tripeptide (MTP) adjuvant.
Materials and Methods
DNA Manipulations. Oligonucleotides were synthesized by the phosphoramidite method using DNA synthesizers (380]3; Applied Biosystems, Inc., Foster City, CA). Gene assembly and site-directed mutagenesis were performed using standard procedures (4).
Yeast Expression and Protein Purification. The synthetic Pfs25
genes were cloned into the yeast vector pBS24 (5) and the resulting plasmids were used to transform yeast strain AB110 (6) . Pfs25-B was purified from yeast supernatants subsequent to removal of yeast cells by continuous flow centrifugation. Supernatants were concentrated and desalted by tangential flow ultrafiltration over a 5-kD membrane. Initial purification was achieved by ion-exchange chromatography on Fast Flow Q resin (Pharmacia Fine Chemicals, Piscataway, NJ), equilibrated with 10 mM Tris/HC1, pH 8.0, 1 mM EDTA, using a 0-0.3 M NaC1 gradient for elution. The elution profile was monitored at A2s0, and the major peak was confirmed as Pfs25-B by SDS-PAGE. Fractions that contained Pfs25-B were pooled, concentrated by ultrafiltration to 10--20 mg/ml, and separated by gel filtration on S-100 HR Sepharose (Pharmacia Fine Chemicals). The column was developed in 2 x PBS and monitored in an identical manner to the ion-exchange purification step. The peak protein fractions were pooled, concentrated, desalted, and the material lyophylized and stored at 4~
Immunizations. In the Freund's adjuvant group, mice were immunized three times at 3-wk intervals with 50 #g of Pfs25-B in a final volume of 100/~1, as described previously (7) . In the MF59 adjuvant groups, mice were immunized, using the same protocol with Pfs25-B, falc 2.3 (7), hEGF (8) , or hSOD (9) (50/~g/injection). Animals were bled 1 wk after the final immunization, and antibody titers were measured in the ELISA format. Monkeys were immunized with Pfs25-B and MF59, or MF59 alone using the same protocol, except that injections were carried out at 4-wk intervals.
Immunized and control animals were bled at 2-wk intervals for ELISAs, and transmission-blocking activities were measured at weeks 12 and 22.
ELISA. ELISAs were performed as described previously (7).
Titers were calculated at 0.2 absorbance units using a Vm~ microtiter plate reader (Molecular Devices, Palo Alto, CA) programmed to read at 650 mm with subtraction of the 490-nm reading.
Antibodies. mAb 4B7 was produced by fusion of spleen cells from a BALB/c mouse immunized twice with recombinant vaccinia virus that were expressing Pfs25, and boosted with whole P.faki~rum gametes. Supernatants from the fusion were screened for specificity to Pfs25 by immunoblot of reduced Pfs25-B (D. C. Kaslow, unpublished observations). Antisera P7 was produced by pooling sera from mice immunized individually with the peptides SLKCLKENETCKAVD, LKENETCKAVDGIYK, KAVDGIY-KCDCKDGF, GIYKCDCKDGFIIDN, and DCKDGFIIDNESSI, which are derived from the fourth EGF-like domain of Pfs25.
Transmission-blocking Assays. Murine or monkey sera were assayed for transmission-blocking activity as described previously (2). Briefly, sera or mAb ascites fluid were mixed in a 1:1 ratio with erythrocyte cultures that contained P. fakiparum gametocytes and the mixtures were fed to Anophelesfreeborni mosquitoes using a membrane feeding apparatus. After 7 d, mosquitoes were dissected and examined for the presence of P. faki~rum oocysts (2).
Results and Discussion
We chemically synthesized a gene for Pfs25 that encoded amino acids 22-190 of the natural 217-amino acid precursor protein (10) , and thereby deleted the proposed NH2-terminal secretory signal sequence. Also deleted was the hydrophobic COOH-terminal region that has been proposed to serve as a signal for attachment of a glycosylphosphatidyl-inositol membrane anchor (10, 11) . Expression and secretion from yeast of this Pfs25 extracellular domain was achieved by fusion of the synthetic gene to DNA sequences encoding the yeast ol factor pheromone secretory signal/leader sequence (8) . Transcription was driven by the glucose-regulated alcohol dehydrogenase 2/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAPDH) hybrid promoter described previously (12) . A second gene was also constructed, in which the three remaining N-linked glycosylation sites at amino acid positions 112, 165, and 187 of the encoded protein (Fig. 1 A) were removed by Asn-*Ala mutation and introduction of a termination codon after Glu188. The removal of glycosylation sites allowed the secretion of a homogeneous product that also contained all four epidermal growth factor (EGF)-like repeats described previously for Pfs25 (Fig. 1 A) (10) . This protein, designated Pfs25-B, was selected for further study.
The secreted protein was purified ( Fig. 1 B) , and analyzed by immunoblotting using rabbit polyclonal antisera to Pfs25 or with the mAb 1C7 (10), a transmission-blocking mAb that had been shown previously to recognize natural Pfs25 only under nonreducing conditions. The purified protein was used to immunize mice and Aotus trivirgatus monkeys with the muramyl tripeptide (MTP) adjuvant MF59, an adjuvant that has been used previously to elicit high antibody titers in rodents and goats with other recombinant malaria proteins (7), and has also been demonstrated to be safe and e~ca-dous in humans when used in conjunction with a yeast-derived HIV-1 envelope protein (13) .
Humoral immune responses elicited in mice with both Freund's adjuvant and MF59 (Table 1) , and in monkeys with MF59 ( Fig. 2) , were measured by ELISA. Also shown are the reactivities of antisera raised with recombinant Pfs25 against various control recombinant proteins from yeast. These include human superoxide dismutase (hSOD) (9), a circumsporozoite (CS) protein from P. falciparum (falc 2.3) (7), and human EGF (8, 14) . In addition, sera from each immunized monkey (12-wk time point) reacted with native Pfs25 on nonreducing immunoblots (Fig. 3 A) .
The ability of sera to block the formation of oocysts in P. fakiparum gametocyte-fed mosquitoes was determined as described previously (2), and the results are shown in Table  2 A. Clearly, murine antisera against Pfs25-B from either Freund's or MF59-adjuvanted mice were able to dramatically reduce or even abolish the sexual development of the parasite within the mosquito midgut. Only one oocyst was detected in 37 mosquitoes dissected from the immune sera groups, whereas all 16 control, preimmune sera-fed mosquitoes developed oocysts, with an average number of eight per mosquito. This is comparable with results obtained using the transmission-blocking mAb 1D3. This mAb, at a dilution of 1:2 of ascites fluid, fully blocked oocyst development in all 16 mosquitoes tested ( Table 2 A (7) at four weekly intervals (~). Titers were measured by ELISA every 2 wk, and sera taken at weeks 0, 12, and 22 were used for mosquito feeding experiments ( Table 2 B) .
sisted for nearly 4 mo in one monkey and ;>6 mo in the other ( Table 2 B) . Conformational integrity of Pfs25 has been shown to be extremely important for recognition by mAbs that block transmission. Furthermore, linear or improperly folded epitopes of Pfi25 have not been used successfiflly to elicit transmissionblocking immunity. Expression of the related six-cysteinecontaining hEGF in this yeast system resulted in a correctly folded and disulfide-linked polypeptide (14) . It was, therefore, somewhat surprising that the conformation-dependent neutralizing mAbs 1C7, 1I)2, and 1193, which are known to react with the same epitope of Pfs25, did not react as strongly with the secreted recombinant Pfs25-B as they did with native Pfs25 on nonreducing SDS-PAGE immunoblots (Fig. 3 C) . As the epitopes recognized by these mAbs are destroyed by reduction, but not by SDS, high or low salt concentrations, or extremes of pH (I. A. Quakyi and D. C. Kaslow, unpublished observations), reactivity of mAbs 1C7 and 1D2 by immunoblot with recombinant Pfs25 is a sensitive assay for proper disulfide bond formation at or about the mAb epitope, mAb 1C7 showed dear reactivity with Pfs25-B under nonreducing conditions (Fig. 3 B) . In quantitative studies, however, mAbs 1D2 and 1C7 were found to show markedly reduced reactivities with Pfs25-B when compared with native Pfs25. For example, we could demonstrate extensive reactivity of mAb 1D2 with native Pfs25, which was isolated from 5 x 106 parasites, under conditions where no reactivity could be observed with 10/~g of Pfs25-B (Fig. 3 C) . A typical yield of native Pfs25 has been shown to correspond to ,,o10 #g/109 parasites (10) . This very weak reactivity of mAb 1/)2 with secreted Pfs25-B indicates that this particular transmission-blocking epitope is not completely recreated in the recombinant protein. Removal of potential N-linked glycosylation sites, or lack of a glycosylphosphatidylinositol anchor, could explain these findings. A more likely explanation, however, is improper disulfide bond formation. The disulfide bond structure of the secreted Pfs25-B was examined using two other immunological reagents. P7, an antisera made to a mixture of synthetic peptides from the fourth EGF-like domain of Pfs25, does not recognize native Pfi25. P7 only recognizes fully reduced Pfs25, and thus serves as 3) were fractionated similarly, in the presence (reduced) or absence (nonreduced) of 5 % 2-ME and electroblotted to nitrocellulose (2). Binding of a 1:200 dilution of mAb 1D2 (lanes I and 2), mAb 4B7 (lanes 3 and 4) , or antisera P7 (lane 5). In all cases, electroblotted proteins were detected by alkaline phosphatase-labeled goat anti-mouse sera (PicoBlue; Stratagene). MW, prestained protein markers in kilodaltons (Bethesda Research Laboratories).
an assay for the complete absence of disulfide bonds (I. A. Quakyi et al., manuscript in preparation). P7 reacts with Pfs25-B on reducing but not on nonreducing SDS-PAGE immunoblots, suggesting that Pfs25-B contains some disulfide bonds in the fourth EGF-like domain, mAb 4B7, a previously undescribed mAb to Pfs25 that reacts quite strongly with nonreduced Pfs25 and weakly with reduced Pfs25, dearly reacts with nonreduced Pfs25-B. The reactivity increased markedly upon reduction of Pfs25-B. These data suggest that the mAb 4B7 epitope is improperly formed in Pfs25-B, and further that the decreased reactivity with Pfs25-B, as compared with parasite-produced Pfs25, is not a result of posttranslational modification. Thus, although Pfs25-B appears to possess only partial conformational integrity, the yeastderived product was still fully capable of inducing transmissionblocking immunity in both mice and monkeys.
It has been proposed that the homology of Pfs25 to EGF might give rise to an autoimmune response in individuals immunized with Pfs25. Our data indicate that this is not likely to be the case. First, transmission-blocking antisera did not recognize recombinant hEGF in ELISA (Table 1) , nor did antisera to hEGF recognize Psf25-B in such an assay (Table   1 ). Second, antisera generated against Pfs25-B did not block EGF activity in either cell proliferation (14) or receptor-binding (15) assay systems (data not shown). We anticipate that crossreactivity of antibodies to Pfs25 with hEGF, as well as other members of the polypeptide family that contain EGF-like motifs, may not be a complication of this vaccination strategy.
Several recombinant DNA-derived antigens or synthetic peptides of malaria parasites have been shown to be only weakly immunogenic in humans (16, 17) . Since Pfs25 is not expressed at the gametocyte stage, but appears only during sexual development in the mosquito, and has, therefore, not been subjected to immune pressure in the human host, it might be anticipated that the immunogenicity of Pfs25-B in humans will closely parallel that observed in experimental animals. Furthermore, transmission-blocking immunity elicited in both mice and monkeys was observed with MTP-MF59, an adjuvant that has been shown previously to be safe and efficacious in humans (13) . These studies suggest that recombinant DNA-derived Pfs25 is a promising candidate for the study of transmission-blocking immunity against P. falciparum in humans.
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(A) Sera from mice immunized with Pfs25-B or falc 2.3 (Table 1) were assayed for transmission-blocking activity and compared with the mAb 1D3. Mosquitoes were fed on either the mouse sera or mAb ascites fluid at a 1:2 dilution of the feed (2, 3). Mosquitoes were dissected after 7-8 d, and the numbers of infected mosquitoes and oocysts determined. Infectivity was scored as the number of oocysts found in the sample divided by the number found in the pooled prebleed control ( x 100%). (/3) The ability of sera from two immunized Aotus monkeys to block oocyst development was measured as above. Here, prebleed sera from each monkey (numbers A108 and A142) were used as controls. Transmission-blocking activities were measured at 12 and 22 wk. In this experiment, mAbs 1D2 and 4B7 were also shown to block oocyst appearance at a 1:2 dilution, whereas sera from two monkeys that were injected with MF59 alone failed to inhibit oocyst development at any of the bleeds assayed (not shown).
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